AbbVie and RemeGen Forge Deal for Innovative Bispecific Antibody Targeting Solid Tumors AbbVie and RemeGen have signed an exclusive licensing deal to develop RC148, a groundbreaking bispecific antibody, targeting advanced solid tumors, enhancing cancer immunotherapy.

AbbVie and RemeGen Forge Deal for Innovative Bispecific Antibody Targeting Solid Tumors #United_States #AbbVie #North_Chicago #RemeGen #RC148

Key Findings from Telitacicept's Phase III Trial in Sjögren's Syndrome Unveiled at ACR 2025 The release of Phase III trial results for Telitacicept reveals significant improvements in Sjögren's Syndrome treatment. Explore the impactful data presented at the 2025 ACR.

Key Findings from Telitacicept's Phase III Trial in Sjögren's Syndrome Unveiled at ACR 2025 #China #Yantai #RemeGen #Telitacicept #Sjögren's_Syndrome

Telitacicept Phase III Study Results for Myasthenia Gravis Highlighted for AANEM 2025 Presentation RemeGen's Phase III clinical study results for telitacicept in generalized myasthenia gravis will be presented at the 2025 AANEM Annual Meeting, showcasing its promising potential.

Telitacicept Phase III Study Results for Myasthenia Gravis Highlighted for AANEM 2025 Presentation #China #Yantai #RemeGen #Myasthenia_Gravis #Telitacicept

RemeGen and Santen Forge Exclusive Partnership for Innovative Eye Drug RC28-E in Asia RemeGen has partnered with Santen to develop RC28-E, targeting severe eye diseases in Asia, marking a significant step in ophthalmology.

RemeGen and Santen Forge Exclusive Partnership for Innovative Eye Drug RC28-E in Asia #RemeGen #Santen #RC28-E

RemeGen's Telitacicept Achieves Success in Phase III Trial for Sjögren's Syndrome RemeGen's drug Telitacicept has successfully met its primary endpoint in a Phase III trial for primary Sjögren's syndrome in China.

RemeGen's Telitacicept Achieves Success in Phase III Trial for Sjögren's Syndrome #China #Yantai #RemeGen #Telitacicept #Sjögren's_Syndrome

FDA Approves RemeGen's Bispecific Antibody RC148 for Phase II Trials in the US RemeGen's bispecific antibody, RC148, has received FDA approval to enter Phase II clinical trials in the United States. This marks a significant achievement in cancer treatment.

FDA Approves RemeGen's Bispecific Antibody RC148 for Phase II Trials in the US #China #FDA_Approval #Yantai #RemeGen #RC148

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen After winding up its stem cell therapy operations last month, Vor Bio has reinvented itself as an autoimmune disease-focused biotech.

US #biotech #VorBio has turned to China's #RemeGen to revitalise its pipeline, paying $125 million upfront for rights to a drug already approved in its home market for multiple #autoimmunediseases.

pharmaphorum.com/news/vor-bio...

RemeGen's Telitacicept Receives EMA's Orphan Drug Designation for Myasthenia Gravis Therapy RemeGen's Telitacicept has received Orphan Drug Designation from the EMA, enabling faster access for Myasthenia Gravis patients in Europe.

RemeGen's Telitacicept Receives EMA's Orphan Drug Designation for Myasthenia Gravis Therapy #China #Yantai #RemeGen #Myasthenia_Gravis #Telitacicept

Disitamab Vedotin Shows Exceptional Results as First-Line Treatment for Advanced Gastric Cancer at ASCO 2025 Discover the groundbreaking results of disitamab vedotin in treating HER2-expressing gastric cancer, presenting at ASCO 2025. The study shows remarkable efficacy and safety.

Disitamab Vedotin Shows Exceptional Results as First-Line Treatment for Advanced Gastric Cancer at ASCO 2025 #China #Yantai #RemeGen #Disitamab_Vedotin #HER2_Gastric_Cancer

RemeGen's Telitacicept Receives Approval for Myasthenia Gravis in China RemeGen's innovative drug Telitacicept has been greenlit by China's NMPA for the treatment of generalized myasthenia gravis, heralding new hope for patients.

RemeGen's Telitacicept Receives Approval for Myasthenia Gravis in China #China #Yantai #RemeGen #Myasthenia_Gravis #Telitacicept

Revolutionary Phase 3 Trial Results for Disitamab Vedotin in Urothelial Carcinoma: A New Era of Treatment RemeGen's Phase 3 trial of Disitamab Vedotin shows promising results in treating HER2-expressing urothelial carcinoma, paving the way for new therapies.

Revolutionary Phase 3 Trial Results for Disitamab Vedotin in Urothelial Carcinoma: A New Era of Treatment #RemeGen #Disitamab_Vedotin #HER2

RemeGen Unveils Promising Phase 3 Results of Telitacicept for Myasthenia Gravis Treatment Telitacicept shows remarkable efficacy in Phase 3 trials for generalized myasthenia gravis, potentially transforming treatment for patients.

RemeGen Unveils Promising Phase 3 Results of Telitacicept for Myasthenia Gravis Treatment #USA #San_Diego #RemeGen #Myasthenia_Gravis #Telitacicept

Breakthrough Phase II Clinical Trial Results for Bladder Cancer Treatment at ASCO GU 2025 Recent data from a Phase II trial showcases the effectiveness of Disitamab Vedotin and Toripalimab for treating bladder cancer, offering hope for patients.

Breakthrough Phase II Clinical Trial Results for Bladder Cancer Treatment at ASCO GU 2025 #USA #San_Francisco #RemeGen #Disitamab_Vedotin #Toripalimab

RemeGen Breakthrough in HER2-Positive Advanced Breast Cancer Treatment Unveiled at 2024 SABCS RemeGen showcased pivotal Phase III data for Disitamab Vedotin, a novel treatment for HER2-positive advanced breast cancer at the 2024 SABCS.

RemeGen Breakthrough in HER2-Positive Advanced Breast Cancer Treatment Unveiled at 2024 SABCS #China #Yantai #RemeGen #Disitamab_Vedotin #HER2-positive